News

Published on 23 Nov 2022 on Zacks via Yahoo Finance

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio


Article preview image

Glaukos Corporation GKOS is well-poised for growth, backed by favorable clinical trial results and a robust product pipeline. However, stiff competition remains a concern.

Shares of this Zacks Rank #3 (Hold) have gained 6.3% against the industry’s decline of 29.2% on a year-to-date basis. The S&P 500 Index has fallen 18.3% in the same time frame.

Glaukos — with a market capitalization of $2.25 billion — is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 16.3% for 2023 and expects to sustain its strong performance. The company has a trailing negative four-quarter earnings surprise of 7.6%, on average.

NYSE.GKOS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y

Glaukos Corporation GKOS reported a fourth-quarter 2023 adjusted loss of 63 cents per share, 12.5...

Zacks via Yahoo Finance 22 Feb 2024

Glaukos Corporation (NYSE:GKOS) Q4 2023 Earnings Call Transcript

Glaukos Corporation (NYSE:GKOS) Q4 2023 Earnings Call Transcript February 21, 2024 Glaukos Corpor...

Insider Monkey via Yahoo Finance 22 Feb 2024

Is Glaukos Corporation (NYSE:GKOS) Trading At A 41% Discount?

Key Insights Glaukos' estimated fair value is US$155 based on 2 Stage Free Cash Flow to EquityGla...

Simply Wall St. via Yahoo Finance 21 Feb 2024

The Zacks Analyst Blog Highlights Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest...

For Immediate Release Chicago, IL – February 14, 2024 – Zacks.com announces the list of stocks fe...

Zacks via Yahoo Finance 14 Feb 2024

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos Corporation GKOS is well-poised for growth, backed by favorable clinical trial results an...

Zacks via Yahoo Finance 14 Feb 2024

Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand

Glaukos Corporation GKOS announced preliminary revenue results for fourth-quarter 2023. The preli...

Zacks via Yahoo Finance 11 Jan 2024

Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?

Shares of Glaukos Corporation GKOS scaled a new 52-week high of $81.84 on Dec 15, before closing ...

Zacks via Yahoo Finance 18 Dec 2023

Glaukos (NYSE:GKOS) shareholders have earned a 37% return over the last year

While Glaukos Corporation (NYSE:GKOS) shareholders are probably generally happy, the stock hasn't...

Simply Wall St. via Yahoo Finance 14 Dec 2023

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos Corporation GKOS is well-poised for growth, backed by favorable clinical trial results an...

Zacks via Yahoo Finance 15 Nov 2023

What Is Glaukos Corporation's (NYSE:GKOS) Share Price Doing?

While Glaukos Corporation (NYSE:GKOS) might not be the most widely known stock at the moment, it ...

Simply Wall St. via Yahoo Finance 3 Nov 2023